A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors

被引：0

作者：

Hua, Y. ^{[1
,9
]}

Wang, C. ^{[1
,9
]}

Li, F. ^{[2
]}

Han, Y. ^{[3
]}

Zuo, D. ^{[1
,9
]}

Lv, Y. ^{[1
,9
]}

Peng, Y. ^{[4
]}

Chen, J. ^{[5
,6
]}

Yuan, R. ^{[7
]}

Zhang, F. ^{[8
]}

Wang, Y. ^{[10
]}

Wu, H. ^{[10
]}

Zhou, G. ^{[10
]}

Wang, S. ^{[3
]}

Li, N. ^{[3
]}

Lu, Y. ^{[11
]}

Lin, Q. ^{[12
]}

机构：

[1] Shanghai Jiao Tong Univ, Dept Orthoped, Peoples Hosp 1, Shanghai Gen Hosp, Shanghai, Peoples R China

[2] Beijing GoBroad Boren Hosp, Dept Hepatobiliary Oncol, GoBroad Med Hematol, Beijing Res Ctr, Beijing, Peoples R China

[3] Chinese Acad Med Sci, Peking Union Med Coll, Natl Canc Ctr, Clin Trial Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept VIP Med Serv, Natl Canc Ctr, Beijing, Peoples R China

[5] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA

[6] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA

[7] Dowlin Biomed, Dept Immunotherapy, Hooksett, NH USA

[8] Dept Immunol, Hillsboro, OR USA

[9] Shanghai Jiao Tong Univ, Shanghai Bone Tumor Inst, Shanghai Gen Hosp, Dept Orthoped Oncol,Sch Med, Shanghai, Peoples R China

[10] Joint Biosci SH Ltd, Shanghai, Peoples R China

[11] Peking Univ, Dept Hepatobiliary Oncol, Med Ctr 302, Hlth Sci Ctr, Beijing, Peoples R China

[12] Hebei Med Univ, Dept Oncol, North China Petr Bur Gen Hosp, Shijiazhuang, Hebei, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1052

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

993MO

引用

页码：S677 / S677

页数：1

共 50 条

[1] A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
Johnson, Melissa Lynne
Wang, Judy Sing-Zan
Falchook, Gerald Steven
Charlton, Julie
MacDonald, Alexander
Strickland, Donald
Jones, Suzanne Fields
Pease, Elizabeth J.
Brugger, Wolfram
Burris, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
Minami, Hironobu
Ando, Yuichi
Ma, Brigette Buig Yue
Lee, Jih-Hsiang
Momota, Hiroyuki
Fujiwara, Yutaka
Li, Leung
Fukino, Koichi
Ito, Koji
Tajima, Takeshi
Mori, Asuka
Lin, Chia-Chi
CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
[3] A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
Park, Jong Chul
Butler, Marcus O.
Curti, Brendan D.
Emens, Leisha A.
Pastor, Danielle M.
Elassal, Joseph
Kaufman, Howard L.
Kirkwood, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
Tolcher, Anthony W.
Victoria, Ivan
Germann, Nathalie
Luecke, Stephan
Bailey, Mark
Kordes, Maximilian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors
Patel, Manish R.
Falchook, Gerald S.
Wang, Judy S.
Imedio, Esteban Rodrigo
Kumar, Sanjeev
Miah, Kowser
Mugundu, Ganesh M.
Jones, Suzanne F.
Spigel, David R.
Hamilton, Erika P.
TARGETED ONCOLOGY, 2025, 20 (01) : 127 - 138
[6] Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
Patel, Manish R.
Falchook, Gerald Steven
Wang, Judy Sing-Zan
Imedio, Esteban Rodrigo
Kumar, Sanjeev
Motlagh, Pejvack
Miah, Kowser
Mugundu, Ganesh M.
Jones, Suzanne Fields
Spigel, David R.
Hamilton, Erika Paige
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Myint, Han
Shah, Satish
Gutierrez, Martin
Zsiros, Emese
Nelson, Megan
Zeidan, Stephanie
Myrthil, Nadia
Morawski, Aaron
Barbu, Alina
Shaik, Jahangheer
Zhou, Chelsea
Kanellopoulou, Chrysi
Copeland, Ron
Cusumano, Zachary
Flies, Dallas
Langermann, Solomon
Lorusso, Patricia
Odunsi, Kunle
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
[8] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
Gutierrez, Martin
Hamid, Omid
Shum, Elaine
Wise, David R.
Balar, Arjun Vasant
Weber, Jeffrey S.
LoRusso, Patricia
Shafi, Saba
Rimm, David L.
Tolcher, Anthony W.
Basudhar, Debashree
Dujka, Melanie Elizabeth
Heller, Kevin N.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
Gutierrez, Martin
Janku, Filip
Tian, Linjie
Luke, Jason J.
Shum, Elaine
Shin, John
Weiss, Ido
Liu, Linda N.
Files, Dallas
Langermann, Solomon
Myint, Han
Bilusic, Marijo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] A phase I/IIa, open-label, dose-escalation and expansion study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ107 in Chinese patients with advanced solid tumors
Li, Jin
Guo, Ye
Peng, Wei
Xue, Junli
Zhao, Wei
Ge, Xiaoxiao
Xue, Liqiong
Tang, Wenbo
Zhou, Li
Zhang, Min
Guo, Bingshi
Wang, Liping
Guo, Jiyuan
Cui, Feifei
Suo, Haiyun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

← 1 2 3 4 5 →